Heart Failure Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Mesoblast, Rivus Pharmaceuticals, Heartseed Inc, StemCardia, Eli Lilly and Company, BioCardia, Bristol

Heart Failure Pipeline constitutes 70+ key companies continuously working towards developing 75+ Heart Failure treatment therapies, analyzes DelveInsight.

Heart Failure Overview:

Heart failure (HF) is a condition caused by structural and functional abnormalities in the heart muscle, leading to impaired ventricular filling or blood ejection. The most common cause of HF is a decrease in left ventricular function. Key factors contributing to HF include increased hemodynamic stress, ischemic damage, ventricular remodeling, excessive neuro-humoral activation, abnormal calcium handling in heart cells, irregular growth of the extracellular matrix, accelerated cell death, and genetic factors. Typical symptoms of congestive heart failure include fatigue, shortness of breath, swollen ankles, and difficulty exercising, along with symptoms related to the underlying cause. However, diagnosing HF based solely on clinical symptoms can be challenging, especially in women, older adults, or those who are obese. The risk of death increases with each hospitalization for HF. Recurrent hospitalizations, sudden acute episodes, or complications from HF can indicate more advanced stages of the disease.

When categorizing heart failure, the most important factor is whether the left ventricular ejection fraction (LVEF) is preserved or reduced (below 50%). A reduced LVEF in systolic heart failure is a strong indicator of increased mortality. Between 40-50% of HF patients have diastolic heart failure with preserved left ventricular function. Diastolic HF patients are typically older, more likely to be female, and have conditions like hypertension, atrial fibrillation, and left ventricular hypertrophy. Unlike systolic heart failure, which has established treatment guidelines, diastolic heart failure lacks evidence-based treatment options. Survival rates are similar between diastolic and systolic heart failure, with differences primarily attributable to ejection fraction.

Request for a detailed insights report on Heart Failure pipeline insights @ https://www.delveinsight.com/report-store/heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Heart Failure Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Heart Failure Therapeutics Market.

Key Takeaways from the Heart Failure Pipeline Report

DelveInsight's Heart Failure pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Heart Failure treatment.
In December 2024, Cytokinetics, Incorporated (Nasdaq: CYTK) announced the start of patient enrollment for COMET-HF (Confirmation of Omecamtiv Mecarbil Efficacy Trial in Heart Failure), a Phase 3 confirmatory trial assessing omecamtiv mecarbil in individuals with symptomatic heart failure (HF) and significantly reduced ejection fraction. Omecamtiv mecarbil is a novel investigational cardiac myosin activator being developed as a potential treatment for this condition. The trial is being conducted in partnership with the Duke Clinical Research Institute (DCRI), a prestigious academic research organization.
In October 2024, Viatris signed an exclusive licensing agreement with Lexicon Pharmaceuticals for INPEFA (sotagliflozin) in all regions outside the US and EU.
In September 2024, Bayer revealed the late-breaking Phase III FINE-HEART trial data for KERENDIA (finerenone) during a Hot Line session at the European Society of Cardiology (ESC) Congress 2024.
In August 2024, Eli Lilly and Company (NYSE: LLY) reported positive topline results from the SUMMIT Phase 3 trial, which evaluated tirzepatide injection (5 mg, 10 mg, and 15 mg) in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. Tirzepatide demonstrated statistically significant improvements in both primary endpoints, including a reduced risk of heart failure events (composite endpoint) and improved heart failure symptoms and physical limitations, as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS), compared to placebo.
In May 2024, Eli Lilly and Company announced an additional USD 5.3 billion investment to expand manufacturing at its new Indiana site, aimed at increasing API production for tirzepatide and other pipeline drugs.
AstraZeneca is expecting the Phase III BalanceD-HF trial results for balcinrenone (AZD9977) combined with dapagliflozin for heart failure in 2025.
Key Heart Failure companies such as Mesoblast, Rivus Pharmaceuticals, Heartseed Inc, StemCardia, Eli Lilly and Company, BioCardia, Bristol Myers Squibb, Sardocor Corp., AstraZeneca, Tenaya Therapeutics, Salubris Bio therapeutics, Moderna Therapeutics, Cytokinetics, Eli Lilly and Company, Applied Therapeutics, Help Therapeutics, Stealth BioTherapeutics, Actelion Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Merck & Co, Servier, Lexicon Pharmaceuticals, Windtree Therapeutics, and others are evaluating new drugs for Heart Failure to improve the treatment landscape.
Promising Heart Failure pipeline therapies in various stages of development include Rexlemestrocel-L, HU 6, HS-001, Ribonucleotide reductase based gene therapy, and others.

Heart Failure Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Heart Failure Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Heart Failure treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Heart Failure market.

Download our free sample page report on Heart Failure pipeline insights @ https://www.delveinsight.com/sample-request/heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Heart Failure Emerging Drugs

Rexlemestrocel-L: Mesoblast
HU 6: Rivus Pharmaceuticals
HS-001: Heartseed Inc
Ribonucleotide reductase based gene therapy: StemCardia

Heart Failure Companies

Around 70+ major companies are working on developing therapies for Heart Failure. Among them, Mesoblast is one of the companies with drug candidates for Heart Failure in the most advanced stage, specifically phase III.

DelveInsight's report covers around 75+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Heart Failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Heart Failure Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Heart Failure Therapies and Key Companies: Heart Failure Clinical Trials and advancements @ https://www.delveinsight.com/report-store/heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Heart Failure Pipeline Therapeutic Assessment
• Heart Failure Assessment by Product Type
• Heart Failure By Stage
• Heart Failure Assessment by Route of Administration
• Heart Failure Assessment by Molecule Type

Download Heart Failure Sample report to know in detail about the Heart Failure treatment market @ Heart Failure Therapeutic Assessment @ https://www.delveinsight.com/sample-request/heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Heart Failure Current Treatment Patterns
4. Heart Failure - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Heart Failure Late-Stage Products (Phase-III)
7. Heart Failure Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Heart Failure Discontinued Products
13. Heart Failure Product Profiles
14. Heart Failure Key Companies
15. Heart Failure Key Products
16. Dormant and Discontinued Products
17. Heart Failure Unmet Needs
18. Heart Failure Future Perspectives
19. Heart Failure Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Heart Failure Pipeline Reports Offerings: https://www.delveinsight.com/report-store/heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.